Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1244 views | HTML 2537 views | ?
Hamid Sayar1,*, Yan Liu4,*, Rui Gao4, Mohammad Abu Zaid1, Larry D. Cripe1, Jill Weisenbach5, Katie J. Sargent5, Mehdi Nassiri2, Lang Li3, Heiko Konig1, Attaya Suvannasankha1, Feng Pan4, Rajasubramaniam Shanmugam1,7, Chirayu Goswami3, Reuben Kapur4, Mingjiang Xu4 and H. Scott Boswell1,6
1 Indiana University Melvin and Bren Simon Cancer Center, Department of Medicine, Hematology/Oncology Division, Indiana University School of Medicine, Indianapolis, IN, USA
2 Department of Hematopathology, Indiana University School of Medicine, Indianapolis, IN, USA
3 Biostatistics and Computational Biology, Indiana University School of Medicine, Indianapolis, IN, USA
4 Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA
5 Indiana University Health Systems, Indianapolis, IN, USA
6 Veterans Affairs Medical Center, Indianapolis, IN, USA
7 ICMR, National Institute for Research in Tribal Health, Jabalpur, India
* These authors contributed equally to this work
Hamid Sayar, email:
Yan Liu, email:
Keywords: AML; sorafenib; vorinostat; bortezomib; epigenetics
Received: August 25, 2017 Accepted: October 25, 2017 Published: December 25, 2017
Co-occurrence of Flt3ITD and TET2 mutations provoke an animal model of AML by epigenetic repression of Wnt pathway antagonists, including RUNX3, and by hyperexpression of ID1, encoding Wnt agonist. These affect HOXA over-expression and treatment resistance. A comparable epigenetic phenotype was identified among adult AML patients needing novel intervention. We chose combinations of targeted agents acting on distinct effectors, at the levels of both signal transduction and chromatin remodeling, in relapsed/refractory AML’s, including Flt3ITD+ve, described with a signature of repressed tumor suppressor genes, involving Wnt antagonist RUNX3, occurring along with ID1 and HOXA over-expressions. We tracked patient response to combination of Flt3/Raf inhibitor, Sorafenib, and Vorinostat, pan-histone deacetylase inhibitor, without or with added Bortezomib, in consecutive phase I trials. A striking association of rapid objective remissions (near-complete, complete responses) was noted to accompany induced early pharmacodynamic changes within patient blasts in situ, involving these effectors, significantly linking RUNX3/Wnt antagonist de-repression (80%) and ID1 downregulation (85%), to a response, also preceded by profound HOXA9 repression. Response occurred in context of concurrent TET2 mutation/hypomorphy and Flt3ITD+ve mutation (83% of complete responses). Addition of Bortezomib to the combination was vital to attainment of complete response in Flt3ITD+ve cases exhibiting such Wnt pathway dysregulation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.